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ABSTRACT
Numerous meta-analyses on inotropes (dobutamine) and inodilators (milrinone, levosimendan) suggest that 
their impact on survival are at best neutral (but may be deleterious) whereas levosimendan seems to have 
beneficial effects on survival in patients with acute heart failure (AHF) syndromes. The aim of this essay is 
to attempt to explain these results through a conceptual framework of cardiocirculatory (patho)physiology. 
Many clinical studies in AHF have been based and interpreted on a ‘cardiocentric’ framework. The three 
above-mentioned categories of drugs are thought to increase cardiac output (CO) by increasing only 
heart muscle contraction (inotropes) or by also decreasing systemic vascular resistance (inodilators). We 
complement this ‘cardiocentric’ framework with a more integrated one based on (i) the effects of drugs on 
venous return (VR), equal to CO (VR is the difference between mean systemic and right atrial pressures 
divided by venous resistance; maintenance of adequate VR depends on the stressed blood volume); 
inodilators may decrease the stressed volume and therefore may decrease VR; (ii) the coupling of the left 
ventricle–aorta and right ventricle–pulmonary artery (dependent on the compliance of the large arteries), 
which is increased by inodilators in the absence of measurable effects on arterial systemic/pulmonary 
pressures) and (iii) the vascular waterfall phenomenon, which explains that inodilators, by decreasing 
intra-organ arterial resistance, can improve organ perfusion even in previously mildly hypotensive patients 
(in the absence of cardiogenic shock). The challenge is to transform these concepts into clinical tools to 
guide therapy in AHF syndromes. 
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Introduction
The use of beta-blockers in chronic heart failure 
was, in effect, prohibited 25 years ago because the 
interpretation of physiology was considered to make 
their use reckless and dangerous. In the years since, 
re-appraisal of the interplay between physiology and 
pharmacology has created a situation in which the 
use of beta-blockers in chronic heart failure is almost 
mandatory, and the withholding of these drugs is now 
considered reckless and dangerous. 
As the fortunes of beta-blockers have risen so the 
status of inotropic drugs has faded. In recent years, 
however, there has been a new interest in these drugs 
and, in particular, an interest, also grounded in re-ap-
praisals of physiology, in differentiating between drugs 
that are exclusively inotropic and drugs that also act to 
dilate parts of the vascular system, arterial or venous.
Knowledge, clinical practice and clinical studies on 
this question are based are the following concepts and 
premises (Fig. 1).
(i) A pure inotrope would increase heart muscle 
contraction, although this is difficult to measure di-
rectly in clinical practice (e.g. dP/dt measurements 
for ventricular contractility) and is often assessed 
using a surrogate such as cardiac output (CO) or, 
less frequently, left ventricular (LV) ejection fraction 
(LVEF).
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Meta-analyses may  be criticized [11], but it is 
reasonable to assume that similar methodological 
limitations apply to all meta-analyses of inotropes and 
inodilators. Furthermore, while meta-analyses tell us 
which drugs affect/do not affect outcomes they do 
not reveal why or how individual drugs exert their ef-
fects. For answers to these questions, we must refer to 
physiology and pathophysiology, two fields of medicine 
that are frequently overlooked in day-to-day practice. 
The goal of this essay is to attempt an explanation of 
how and why inodilators (and by extension inotropes) 
do/do not improve outcome. 
The first explanation, on which probably most in-
vestigators and clinicians would agree, is that despite 
efforts to better define the phenotypes of acute, chronic 
or chronic decompensated ‘heart failure’ the problem is 
still complex and that in both prospective randomized 
trials and meta-analyses there is impressive hetero-
geneity among patients diagnosed with heart failure. 
Noticeably, improved haemodynamic status, estimated 
by a variety of endpoints, is not always associated with 
improved survival in either the short or long term [12]. 
The second explanation, perhaps less obvious, is 
that our view of the cardiocirculatory system, in both 
normal and pathophysiological circumstances, is ‘car-
diocentric’. This is substantially due to the availability of 
monitoring devices (e.g. the pulmonary artery catheter 
and echocardiography) that provide easy access to pre-
dominantly cardiac indices. In the next part of this essay, 
we will attempt to complement this ‘cardiocentric’ view 
with an integrated view of the cardiocirculatory system. 
Cardiocentric versus an integrated view 
of the cardiocirculatory system
In the ‘cardiocentric’ view, CO is the product of LV 
ejection (stroke) volume and heart rate. In the integrated 
view, at equilibrium (i.e. within the time frame of several 
heartbeats), CO and venous return (VR) are equal. VR is 
determined by blood volume, venous tone and cardiac 
activity [13–15]. Of note, the right and left venous returns 
must be nearly equal. 
Blood volume is mainly located within the venous 
system (60–70% of total blood volume), with the re-
mainder distributed among the heart, lungs, arteries 
and arterioles [13, 14]. The total blood volume (Vt) is 
the sum of: 
(i) the unstressed blood volume (Vu; the volume nec-
essary to fill the circulatory system to its maximum 
capacity without an increase in the transmural 
pressure), and
(ii) the stressed blood volume (Vs; the difference be-
tween Vt and Vu).
SVR
CO = EV x HR
MAP–Pra
CO =
Inotrope Vasodilator Inodilator
Figure 1. The ‘cardiocentric’ view of the mechanisms of an 
inotrope, an inodilator and a vasodilator. A pure inotrope 
would theoretically increase ejection (stroke) volume. An 
inodilator would increase ejection volume and decrease 
systemic vascular resistance. A vasodilator would decrease 
systemic vascular resistance. CO — cardiac output; EV 
— ejection volume; HR — heart rate; MAP — mean arterial 
pressure; Pra — right atrial pressure; SVR — systemic 
vascular resistance
(ii) An inodilator would do (i) and would also decrease 
systemic vascular resistance to some extent (the 
precise balance of effects would vary from drug 
to drug).
Within this conceptual framework, many individual 
studies have been performed; more recently, a series 
of meta-analyses have been undertaken, the results of 
which may be summarized as follows.
 — Dobutamine is at best neutral in terms of outcome 
(survival) compared with placebo in patients with 
end-stage cardiac failure [1]. Several studies found 
dobutamine to be associated with a worse outcome 
than placebo in patients with myocardial dysfunc-
tion after cardiac surgery [2]. However, these data 
did not establish a cause-effect relationship for 
this finding.
 — Milrinone, an inodilator that works primarily through 
inhibition of phosphodiesterase (PDE)-III, with only 
a 14-fold selectivity for PDE-IV [3], is at best neutral 
vis-à-vis placebo in terms of outcome in patients 
with heart failure and appears to have deleterious 
effects when only more methodologically robust 
studies are considered [4].
 — Levosimendan, a calcium-sensitizing agent, is asso-
ciated with improved outcome in several clinical set-
tings such as after cardiac surgery [5, 6] or surgical 
coronary revascularization [7], in ICU patients [8], 
and in patients with acute decompensated cardiac 
failure treated outside the operating theatre or ICU 
[9]. A meta-analysis published in 2010 concerning 
patients with acute heart failure suggested that le-
vosimendan improved survival when compared with 
dobutamine but not versus placebo [10]. 
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Vu is haemodynamically ‘inactive’ because for 
a given global performance of the cardiocirculatory 
system it is not altered by its changes in capacity (for 
an unchanged value of the venous compliance). Vu 
can decrease either by venoconstriction (initiated, e.g., 
through activation of the sympathetic nervous system 
[SNS] or the actions of drugs such as alpha1-adrener-
gic agonists) — which results in part-conversion into 
Vs — or increase by venodilation in response to drugs 
that relax the vascular smooth muscle cells (including 
vasodilators and inodilators); this increase in Vu would 
be associated with a decrease in Vs.
Vs accounts, in normal physiological circumstances, 
for ~30% of Vt and is haemodynamically active [16] 
(contributes to global cardiocirculatory performance 
through increased VR).
Vs/Vu ratio can change even in the absence of 
a change in Vt and thus modify the percentage of 
blood volume that is haemodynamically active [16]. 
Mobilization of the blood volume by activation of the 
SNS can involve up to 30% of Vt with two-thirds of this 
30% coming from the splanchnic venous circulation 
[16]. Of note, pharmacologically induced constriction 
of venous smooth muscle cells can result in decreased 
compliance and increased Vs, but also in increased 
venous resistance (Vres), notably of the hepatic veins 
[16]. The global result could thus be a decreased VR 
despite an increase in Vs. Vasodilators and inodilators, 
which are the focus of this article, would decrease Vs 
and would have the capacity to decrease VR (Fig. 2). 
The determinants VR [13, 14] are mean systemic 
pressure (Pms), right atrial pressure (Pra) and Vres, as 
shown in Equation 1:
VR = Pms — Pra/Vres = CO
The determinants of Vres are blood viscosity (h), the 
length of the venous system and the radius of the veins, 
and are shown in Equation 2:
Vres = 8hl/pr4
where h is mainly dependent on haematocrit (h de-
creases with a decrease in haematocrit) and blood 
temperature (h increases with hypothermia) and can be 
changed acutely by a decrease in haematocrit through 
haemodilution secondary to volume expansion with 
sanguinous volume expanders.
Pms is derived according to Equation 3:
Pms = Vs/Csv
where Csv is the mean compliance of the venous 
system that contains Vs. As mentioned previously, Vs 
is the difference between Vt and the Vu, as shown in 
Equation 4:
Pms = (Vt–Vu)/Csv
Equations 3 and 4 show that Pms can change as 
a result of changes in:
 — Vt
 — Vs/Vu ratio
 — Csv
If a vasodilator increases Csv, Pms will decrease 
and, all other variables being equal, so will the VR. 
Hence CO will either decrease or will be maintained by 
an increase in HR through activation of the baroreflex 
even if the drug in question is not directly a positive chro-
notropic drug [16]. This may be the case for inodilators 
if the decreases in Pms and VR are not recognized and 
are not corrected by volume expansion. 
One of the reasons the physiology of VR has not 
gained the attention of the medical community in 
routine clinical practice is because measurement of 
Pms requires an arrest of cardiac activity. This can be 
performed fairly easily in experimental animals and 
exceptional clinical situations (e.g. when inducing 
heart fibrillation to test an implantable defibrillator), but 
its measurement in routine clinical practice has been 
difficult. Recently, Maas and colleagues have proposed 
three methods of measuring or calculating Pms [17–20]. 
The first method consists of stepwise increases in 
intrathoracic pressure in mechanically ventilated and 
sedated patients that allows the determination of Pms 
through extrapolation. The second method consists 
in rapidly (< 1 sec) inflating a cuff around the arm at 
a pressure 50 mmHg above the patient’s systolic blood 
pressure. In this situation, the rapid inflation attenu-
ates/eliminates venous stasis and the pressure that is 
measured (in the radial artery catheter) is equal to that 
in the arm circulation (arterial and venous) distal to the 
inflated cuff. The third method exploits a calculation 
for which the only directly derived data required are 
the Pra and CO. 
The authors of these methods showed that all 
three techniques provide results for Pms but that 
the calculated Pms systematically overestimates the 
measured value [17–19]. It must be admitted that, with 
the exception of the technique of rapid cuff inflation, 
these investigations do not lend themselves to use in 
routine clinical practice (even the cuff method requires 
a dedicated device). 
The authors compared their results for Equation 1 
with results obtained in animals and found that, in both 
settings, the difference between Pms and Pra is only 
~10 mmHg. This is a fairly low-pressure gradient, well 
within the margins of error when measuring venous 
pressures in clinical practice. This implies that any 
estimation of VR will be prone to error. This probably 
explains, at least to some extent, why clinical reasoning 
is predominantly cardiocentric. Figures 1 and 2 outline 
the 'cardiocentric' and integrated paradigms for the 
actions of vasodilators, pure inotropes and inodilators.
A brief overview of venous physiology
The global venous system contains approximately 
70% of Vt but this percentage can vary according to 
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= CO VR = 
 
Rven  
Pms–Pra
Vasodilator/inodilator Inotrope/inodilator 
Figure 2. Integrated view of the mechanisms of an inotrope, 
an inodilator and a vasodilator. A vasodilator or an inodilator 
would decrease mean systemic pressure and could, 
therefore, be able to decrease venous return and therefore 
cardiac output (in the absence of a reflex increase in heart 
rate). VR — venous return; Pms — mean systemic pressure; 
Pra — right atrial pressure; Rven — venous resistance; 
CO — cardiac output
a particular organ. Within the venous compartment, small 
veins and venules contain 70% of Vt. Pressure values are 
10–15 mmHg in small veins and venules, 4–8 mmHg in 
the peripheral hand veins and 1–2 mmHg in the vena 
cava. Portal venous pressure is 7–10 mmHg [16, 21].
One venous circulation of particular importance in 
physiology and pathophysiology is the splanchnic venous 
circulation, which contains ~25% of Vt [16, 21]. Because 
of the very dense sympathetic innervation of the splanch-
nic veins, this ‘splanchnic reservoir’ can be mobilized 
through decreased compliance and a reduction in vein 
diameters. This sympathetic-mediated mobilization is, in 
fact, the reason why blood loss equalling 10–15% of the 
blood volume is not associated with decreased blood 
pressure or CO. Globally, the venous circulations of 
different organs are less prone to regulation by local me-
tabolites and more susceptible to modulation by the SNS. 
Csv is the ratio of a change in volume (DV) to the 
concomitant change in transmural distending pressure 
(DP) = DV/DP. It is a quantitative measure of the elastic-
ity of a vascular bed. Systemic venous compliance is at 
least 30-times higher than arterial compliance [16, 21]. 
The compliance of the systemic circulation is 7-times 
higher than that of the pulmonary circulation and this is 
extremely important for right ventricle–pulmonary artery 
coupling (see below). After a change in CO, changes in 
compliance are observed mostly in the systemic circu-
lation and, to a much smaller extent, in the pulmonary 
circulation. However, the compliance of pulmonary 
veins can be increased following the administration of 
a venodilator drug such as nitroglycerin or a prostacy-
clin analogue and, probably, sildenafil [22]. Of interest, 
the compliance of the pulmonary veins is decreased in 
LV failure, whether with altered or preserved LVEF. Much 
less is known about the compliance of the pulmonary 
artery, but recent data from our laboratory suggest 
that pulmonary arterial and venous tone are similar, at 
least as far as the in vitro response to noradrenaline 
is concerned [23]. The decreased compliance of the 
pulmonary artery, as can be observed in congestive 
states, could render it less elastic and thus alter right 
ventricle–pulmonary artery coupling (see below). 
Compliance in the venous, systemic and pulmonary 
circulations can, of course, be changed by vasodilators 
and inodilators. 
It must be emphasized that there are situations in 
which changes in Vu and compliance are concordant 
(e.g. venoconstrictors would decrease both parameters, 
whereas venodilators would increase them), but there 
are also situations in which the changes in Vu and 
compliance are discordant [16]. 
To add to the complexity, venoconstrictors can in-
crease Vres whereas venodilators decrease it. Although 
Vres is much smaller than arterial resistance, changes in 
Vres must be interpreted in the context of the small pres-
sure gradient in the venous circulation (Equation 1). 
Increased Vres, particularly in the hepatic veins, can 
result in blood stagnation in the splanchnic venous cir-
culation, an increase in portal vein pressure, an increase 
in capillary filtration and inefficient mobilization of Vs 
[16]. One of the most powerful humoral mediators in this 
context is angiotensin II, which results in increased por-
tal vein pressure secondary to increased hepatic vein 
resistance [16]. The determinants of Vres are shown in 
Equation 2. It is to be noted that an acute change in h 
(as observed with acute haemodilution in the presence 
of normovolaemia) would result in decreased Vres and 
thus increased VR. By contrast, haemodilution in the 
presence of hypovolaemia would probably not increase 
VR because of the increase in hepatic vein resistance 
effected by the SNS. 
It is also important to remember that anaesthesia 
may profoundly modulate the effects of venoconstrictors 
[16] and venodilators compared with the non-anaes-
thetized state. Among other mechanisms, anaesthesia 
alters the buffer effects of the baroreflex. Whether se-
dation (a ‘lighter’ form of anaesthesia) produces effects 
intermediate between the awake and the anaesthetized 
states is unknown. 
Ventricle–large artery coupling
The arterial system, both systemic and pulmonary, 
acts as a conduit to deliver blood to the systemic and 
pulmonary circulations. It also acts as a ‘shock-ab-
sorber’ to soften the pulsations generated by the heart 
such that capillary blood flow is almost continuous [24]. 
Central vessels (i.e. the proximal aorta and pulmonary 
artery) exert their cushioning function by virtue of their 
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Figure 3. Ventricular and large artery elastances. Ea 
— arterial elastance; Ees — ventricular elastance
Table 1. A brief overview of the arterial elastance/ventricular elastance (Ea/Ees) ratio in health and disease
— In normal individuals, the Ea/Ees ratio is 0.7–1.3
— There is a physiological increase in aortic Ea with age, due to stiffening of large arteries 
— There is a physiological increase in Ees with age – the Ea/Ees ratio in healthy elderly patients is maintained close to 1
— In patients with congestive heart failure, the Ea/Ees ratio can be up to 4 due to:
• decreased Ees (decreased systolic function)
• increased Ea (via multiple mechanisms)
high content of elastin; distal systemic arteries contain 
progressively less elastin and more collagen. With age-
ing, the aorta stiffens (albeit much less is known about 
the effects of ageing on the proximal pulmonary artery). 
This stiffening of the aorta is manifested clinically in the 
increased pulse pressure observed in elderly patients 
[24], and explains why even a normal stroke volume 
results in higher systolic pressure; it also explains why 
a higher percentage of the stroke volume is forced 
into the peripheral arterial tree in older persons. This 
probably also results in a lower volume of blood in the 
proximal arterial tree during diastole and could be one 
explanation for the lower diastolic pressure observed 
in the presence of stiffening aortas [25]. 
The stiffening of the aorta is responsible for an in-
crease in pulse wave velocity (from 5 m/sec in young 
adults to 10 m/sec in elderly patients). The anterograde 
wave is reflected in the periphery (at the level of the renal 
arteries for the lower body). The reflected wave will travel 
more rapidly in stiff aortas, and instead of reaching the 
proximal aorta in late systole or early diastole, as in 
normally elastic aortas, it will arrive in early systole thus 
increasing the systolic pressure and the left ventricular 
work. The loss of the reflected wave in diastole explains 
the reduction in diastolic pressure, which is the driving 
pressure of the coronary circulation. 
Under physiological conditions, the functions of the 
ventricles (left or right) and their associated major arter-
ies are coupled. From a pressure–volume curve (Fig. 
3) it is possible to calculate the ventricular end-systolic 
pressure–volume relationship. By changing the preload 
through vena caval occlusion (in experimental animals) 
or by the injection of a pure alpha-adrenergic agonist 
in humans [26] it is possible to generate a family of 
ventricular pressure–volume curves, the end-systolic 
points of which are aligned on a straight line. This line 
represents the LV elastance (Ees) and its slope is an 
estimate of ventricular inotropism — the more vertical 
the slope, the higher the inotropic function. The ventric-
ular afterload may be quantified as the effective arterial 
elastance (Ea), which is the ratio between ventricular 
end-systolic pressure and the stroke volume.  
The ratio of Ea/Ees is close to 1 (ventriculo-arterial 
coupling) under physiological conditions. Table 1 illus-
trates some of the changes that may be encountered 
under both physiological conditions (i.e. ageing) and 
during cardiac failure.  
Alteration of ventricular–large artery coupling will put 
the ventricle into a deleterious energetic situation. The 
most impressive illustration of the impact of increased 
Ea (stiffening of the aorta) comes, paradoxically, from 
humans with aortic valve stenosis. Many clinicians be-
lieve that the increased afterload of the left ventricle in 
patients with aortic stenosis comes from the decreased 
surface of the aortic valve. Accordingly, few would dare 
use a vasodilator such as sodium nitroprusside because 
of the fear of decreasing preload. However, Khot et al. 
[27] demonstrated that in patients with severe aortic 
stenosis and low LVEF, who were in critical circum-
stances while awaiting aortic valve surgery (pulmonary 
oedema and severe dyspnoea), sodium nitroprusside 
increased cardiac index, with a minimal decrease in 
the aortic pressure and no increase in heart rate. The 
most plausible explanation, based also on simulations 
from clinical data [28], is that sodium nitroprusside 
was able to improve left ventricle–aorta coupling. This 
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example illustrates the importance of considering left 
ventricle–aorta coupling, and not only the effects on SVR 
when analysing the effects of vasodilators. 
There are several lines of evidence indicating that 
inodilators (e.g. levosimendan) can restore the Ea/Ees 
ratio to normal, with minimal changes in mean arterial 
pressure (Pa). This has been nicely demonstrated 
by Guarracino et al. [26] in patients who underwent 
coronary artery bypass graft surgery. These authors 
demonstrated that in patients who did not have severe 
alteration of LV function but already had an abnormally 
high Ea/Ees ratio, levosimendan was able to restore 
the Ea/Ees ratio to a normal value. Of interest, because 
these patients did not have heart failure or were not 
in a congestive state, levosimendan also decreased 
preload (and hence ejection volume) and activated 
the baroreflex, so increasing the heart rate. This is also 
probably what happened in the SURVIVE study [29]. 
The impact of an altered Ea/Ees ratio on the left 
ventricle has been appreciated for many years, but only 
in a more recent study has it been demonstrated that 
similar effects operate meaningfully in the pulmonary 
circulation [30]. In normal dogs, Ees was 1.17 and 
Ea was 0.64, with a resulting Ees/Ea ratio of 1.81. In 
dogs with experimental heart failure, borderline pul-
monary arterial hypertension and right ventricular 
dysfunction, Ees was 1.46 and Ea was 1.90 (due 
to the high pulmonary Pa values), with an Ees/Ea 
ratio of 0.7. Milrinone was able to bring the Ees/Ea 
ratio back towards normal values (Ees increased to 
2.43 with an unaltered Ea of 1.9, resulting in an Ees/Ea 
ratio of 1.28). Several other reports, mainly involving 
paediatric patients, suggest that an alteration of the 
pulmonary artery pulsatility (just as for the systemic 
circulation) is associated with worse outcomes [31]. 
Experimental models also demonstrate that decreased 
compliance of the pulmonary artery, mainly due to 
loss of elastin, alters right ventricle–pulmonary artery 
coupling [32]. We hypothesize that in addition to 
structural changes in the pulmonary artery, altered 
right ventricle–pulmonary artery coupling might be 
secondary to decreased pulmonary artery compliance 
because of acute pulmonary artery dilatation second-
ary to both congestions and to altered pulmonary 
artery–vein coupling. The increased stiffening of the 
pulmonary veins is probably secondary to altered LV 
function (both systolic and diastolic) and decreased 
compliance through activation of the SNS. 
Drugs, such as vasodilators and inodilators (includ-
ing levosimendan), that increase pulmonary vessel 
compliance could improve right ventricular function 
[33, 34]. Given the fact that the compliance of the 
pulmonary circulation is 7-times less than that of the 
systemic circulation, it is easy to imagine that alteration 
of the compliance of the pulmonary circulation will be 
an initial event in cases of congestion. Alteration of the 
ventricular–large artery coupling, both left and right, 
is not easily measurable in clinical practice and is not 
visible from the measurement of CO, Pa or calculation 
of the systemic or pulmonary vascular resistance. In 
a recent population study of patients with heart failure 
(both with altered and preserved LVEF), pulmonary 
hypertension (defined as pulmonary artery systol-
ic pressure > 35 mmHg) was found in 79% of the 
1046 patients [35]. Pulmonary arterial hypertension 
was not associated with LV systolic dysfunction but was 
associated with diastolic dysfunction. The mechanisms 
incriminated were the passive backward transmission 
of the elevated LV end-diastolic pressure to the pulmo-
nary veins associated with active vasoconstriction and 
remodelling of the pulmonary arteries (intimal fibrosis, 
medial hypertrophy). All above-cited mechanisms will 
decrease the compliance of the pulmonary circulation 
and alter the right ventricle–pulmonary artery coupling. 
The vascular waterfall phenomenon
Total SVR is calculated as SVR = (Pa — Pra)/CO, 
based on the concepts taken from the electrical circuit 
theory. Such calculation of the SVR implies a constant 
pressure decrease from the input to the output pressure. 
If this concept were true, when the flow is zero, then 
Pa should equal central venous pressure (Pcv). In fact, 
numerous experimental settings have demonstrated 
that this concept of constant pressure decrease is false. 
It was demonstrated in the canine coronary circulation 
that when the coronary flow was zero, the pressure 
was 30–50 mmHg while Pcv was 5–10 mmHg (see 
Magder [36] and references therein). These results 
are explained by the fact that there are two in-series 
resistors. The first is arterial, from the input Pa to the 
arterial critical closing pressure (Pcc; defined as the 
pressure under which the flow from the arterial to the 
venous side of the circulation is stopped despite the 
persistence of a pressure gradient). The second resis-
tor is venous, from the Pms to the Pra (see Equation 
1). The pressure decrease between Pcc and Pms is 
called the vascular waterfall or Starling resistor [36]. 
The Pcc can be measured in experimental settings 
[36] or calculated in patients [37]. These concepts 
are illustrated in Figure 4. Total vascular resistance 
(SVR for the systemic circulation) does not exist from 
a physiological point of view and the calculated SVR 
exceeds the sum of the arterial (Ra in Figure 4) and 
venous (Rves) resistances. Experimentally, but also 
in clinical practice, it has been shown that Pcc is the 
site of action of vasoactive drugs (vasodilators and 
vasoconstrictors) [38] and is also regulated by the 
SNS [37]. Vasoactive drugs and interventions such as 
106
MEDICAL RESEARCH JOURNAL 2020. vol. 5. no. 2
www.journals.viamedica.pl/medical_research_journal
Figure 4. Representation of the total systemic vascular resistance as the sum of the arterial resistance (Ra) and the 
venous resistance (Rven). Pa — input arterial pressure; Pcc — critical closing pressure; Pms — mean systemic pressure; 
CO — cardiac output; Pcv — central venous pressure. Modified from Maas et al. [37]
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volume expansion could act differently on the arterial 
and venous resistors, and flow through vital organs 
is regulated in a more complex manner than can be 
accounted for by calculation of the SVR. The physio-
logical significance of the vascular waterfall has been 
summarized by Magder [36] as follows.  
(i) Flow to organs that autoregulate (heart, brain, kid-
ney) is regulated not by the Pa–Pv gradient but by 
the Pa–Pcc gradient. If a vasodilator or inodilator 
decreases both Pa and Pcc similarly or Pcc more 
than Pa, the intra-organ flow will be maintained or 
even increased. Interestingly, maximum vasodilation 
will not eliminate the vascular waterfall [39]. The 
vascular waterfall phenomenon could explain the 
results of Mebazaa et al. [40] which showed that 
in patients with heart failure, vasodilators, but also 
levosimendan, improved survival even in patients 
with systolic hypotension. On the contrary, if an 
inotrope/vasoconstrictor increases the Pcc more 
than the Pa, the intra-organ resistance will increase 
and the flow will decrease.
(ii) The existence of the Starling resistor at the level of 
arterioles explains why an increase in Pv (Valsalva 
manoeuvre or cough), though it increases Vres, 
will not decrease the Pa–Pcc gradient and flow 
within the organ will be maintained.
(iii) The presence of the Starling resistor explains why, in 
case of a sudden decrease in CO, the pressure will not 
drop as rapidly, and the flow to vital organs such as the 
brain and the heart will be to some extent preserved. 
The Pcc values are lower in the brain and the heart 
than in other territories [37], such as the lower limb. 
From this brief overview of physiology, it seems 
obvious that clinically familiar haemodynamic concepts 
cannot fully explain the complexity of effects that occur 
when a vasoactive drug is administered to a patient. 
The deleterious effects of pure inotropes in patients 
with heart failure or myocardial dysfunction after cardiac 
surgery or in the ICU are probably due to the fact that 
these drugs may:
(i) increase heart rate more than the ejection volume, 
with a resultant increase in myocardial oxygen con-
sumption
(ii) not be efficient in patients under chronic beta-block-
er therapy
(iii) result in rapid desensitization and downregulation 
of the b1-adrenergic receptors
(iv) decrease Pms through b2-adrenergic agonist effects 
and therefore decrease VR
(v) not improve ventricular–large artery coupling by not 
improving large artery compliance
(vi) increase the intra-organ arterial resistance by in-
creasing Pcc. 
By contrast, inodilators could have potential bene-
ficial effects in this situation by virtue of:
(i) having less positive direct chronotropic effects, 
though activation of the baroreflex could still result 
in increased heart rate
(ii) being effective in patients receiving chronic [41] or 
acute [42] beta-blocker therapy
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(iii) improving ventricular–large artery coupling by in-
creasing the compliance of large arteries [32]
(iv) decreasing the intra-organ arterial resistance (and 
therefore increasing intra-organ flow) by decreasing 
Pcc. 
It is also possible that inodilators might exert poten-
tial harmful effects through:
(i) decreasing Pms, thereby decreasing VR (and hence 
CO) with potential activation of the baroreflex; this 
could occur in the absence of corrective measures 
such as increase of Vs by volume expansion
(ii) indirect positive chronotropic effect: this is the 
most likely explanation of the absence of beneficial 
effects of levosimendan in patients with heart failure 
observed in the SURVIVE study [29]. 
Finally, it is possible that the ratio of positive ino-
tropism (and the mechanism of the positive inotropic 
effect) versus vasodilation could explain the results of 
meta-analyses. For instance, it is plausible that the lack 
of beneficial effects of the PDE-III inhibitor milrinone in 
recent meta-analyses [3, 4] PDE-III is due to the fact that 
any gains from its undoubted positive inotropic effects 
[29] are eclipsed by the deleterious effects of increas-
ing the calcium transient within cardiomyocytes. By 
contrast, levosimendan exerts positive inotropic effects 
via increasing the sensitivity of contractile proteins to 
calcium, has direct positive lusitropic effects [43] and 
probably has a more vasodilatory and organ-protective 
profile than milrinone through activation of adenosine 
triphosphate-dependent potassium channels [44–46]. 
These specific effects of levosimendan, as compared 
with inodilators such as milrinone, may explain why le-
vosimendan has beneficial effects on survival in specific 
clinical situations, such as patients undergoing cardiac 
surgery or ICU patients [5–8]. 
To add to the complexity of regulation of the cardio-
circulatory system in health and disease, frequently 
used interventions in the ICU, such as mechanical 
ventilation and drug-induced sedation, will alter the 
venous tone and VR as well as the compliance of large 
arteries [13, 14]. Furthermore, increased intra-abdomi-
nal pressure can increase the resistance of the hepatic 
vein, thus rendering the mobilization of the blood from 
the venous splanchnic reservoir ineffective. 
Conclusions
It seems highly probable that the conceptual frame-
work for haemodynamics should not be limited to the 
‘cardiocentric’ view given the complexity of the phys-
iology and pathophysiology of the cardiocirculatory 
system. The challenge, for the clinician, is to: (i) develop 
clinically validated monitoring tools for variables such 
as Pms or Pcc; (ii) establish therapeutic goals based on 
such monitoring devices; and (iii) review therapy based 
on patient-specific effects of individual drugs and not 
on ‘statistical’ pharmacological effects. Our approach 
may explain why drugs such as levosimendan, effective 
both on cardiac contractility and on load, have a cutting 
edge over pure inotropes.
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